Assessing immune response in psoriasis patients treated with Tildrakizumab
Psoriatic Immune Response to Tildrakizumab
This study tests how the medication Tildrakizumab affects the immune system in people with moderate to severe psoriasis by looking at their skin and blood before and after treatment.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 10 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | University of California, San Francisco Academic / other |
| Drugs / interventions | tildrakizumab |
| Locations | 1 site (San Francisco, California) |
| Trial ID | NCT05390515 on ClinicalTrials.gov |
What this trial studies
This study examines the immune response of patients with moderate to severe psoriasis before and after treatment with Tildrakizumab, an IL23 blocker. It is a one-arm, open-label study involving ten subjects who will undergo biopsy and blood sample collection for molecular profiling. The goal is to evaluate how Tildrakizumab affects immune cell function in the skin and blood of these patients.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with moderate to severe psoriasis affecting more than 5% of their body surface area.
Not a fit: Patients currently taking systemic immunosuppressives, pregnant or breastfeeding women, and those with severe immunodeficiency or active infections may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding of immune responses in psoriasis and enhance treatment strategies.
How similar studies have performed: Other studies have shown promising results with IL23 blockers in treating psoriasis, indicating a potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years of age or older * Patients with moderate-severe psoriasis or \> 5% body surface area affected. Exclusion Criteria: * taking systemic immunosuppressives in the last 4 weeks * pregnancy * severe immunodeficiency (either from genetic or infectious causes). * tuberculosis or other active serious infection * active systemic malignancy. * breast-feeding * Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
Where this trial is running
San Francisco, California
- University of California, San Francisco — San Francisco, California, United States (Recruiting)
Study contacts
- Principal investigator: Raymond Cho, MD, PhD — University of California, San Francisco
- Study coordinator: Raymond Cho, MD, PhD
- Email: rashes@ucsf.edu
- Phone: 415-575-0524
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.